Abstract: A method for preparing mesenchymal stem cells (MSCs) is provided. The method includes providing expanded potential stem cells or a first cell culture including the expanded potential stem cells; culturing the expanded potential stem cells or the first cell culture in a trophoblast stem cell (TSC) differentiation medium to obtain trophoblast stem cells or a second cell culture including the trophoblast stem cells; culturing the trophoblast stem cells or the second cell culture in a mesenchymal stem cell (MSC) differentiation medium to obtain mesenchymal stem cells or a third cell culture including the mesenchymal stem cells; and passaging the mesenchymal stem cells or the third cell culture in an MSC expansion medium while maintaining characteristics of the mesenchymal stem cells.

Abstract: A method for preparing hematopoietic endothelial cells and a method for preparing hematopoietic stem cells are provided, comprising inducing hematopoietic mesodermal cells to express transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at specific time periods during the conversion of induced pluripotent stem cells into the hematopoietic endothelial cells or the hematopoietic stem cells. The method can increase the preparation efficiency of at least one of the hematopoietic endothelial cells and the hematopoietic stem cells (including long-term hematopoietic stem cells).

Abstract: A medium combination and a method for inducing iPSC differentiation to obtain macrophages and use thereof are provided. The medium combination includes a first stage medium to a sixth stage medium. The first stage medium is an E8 complete medium containing a ROCK pathway inhibitor and polyvinyl alcohol, the second stage medium is an E8 complete medium containing a GSK-3? inhibitor, the third stage medium includes an M1 medium and an M2 medium, the fourth stage medium is an M3 medium, the fifth stage medium is an M4 medium, and the sixth stage medium is an M5 medium.

Abstract: The present invention discloses a method and its application for inducing iPSC differentiation to obtain CD34+cells and NK cells. The method utilizes the three-dimensional structure of the embryoid bodies to provide a favorable differentiation microenvironment for iPSC differentiation, and can start producing a high proportion of CD34+cells on the 4th day under hypoxic induction culture conditions. Subsequently, the production of iPSC induced NK cell differentiation is significantly increased by adhering to the embryoid bodies wall or digesting and resuspension induction, And the induced differentiation of NK cells can exert a killing effect on tumor cells in a short period of time, with strong tumor killing ability, suitable for the production and clinical application of large-scale cell preparations.

Abstract: The present invention relates to gene therapy for wet age-related macular degeneration using iPSC-derived cells as vectors. CRISPR technology is used to perform site-directed dual gene editing of iPSCs, neurotrophic factors CNTF and miR-126 are expressed at the same time, and gene-edited IPSCs are then induced to differentiate into RPE cells. The RPE cells obtained by the induced differentiation can repair damaged RPE cells on CNV and inhibit the generation of choroidal neovascularization. In addition, the RPE cells can express the neurotrophic factors CNTF and miR-126 to fundamentally treat wet age-related macular degeneration, which has very good clinical application prospects.

Abstract: Provided are a genetically modified oligodendrocyte progenitor cell, a preparation method therefor and a use thereof. Also provided is a method capable of simultaneously repairing myelin, promoting myelin production, and reducing inflammatory responses and autoimmune damage; the method comprises a genetically engineered oligodendrocyte progenitor cell achieving direct repair of a myelin sheath by means of transplantation of the genetically modified oligodendrocyte progenitor cell, which can alleviate an inflammatory response of the nerve and improve nerve function. This has very good application prospects in the clinical treatment of multiple sclerosis.

Abstract: A rapid and efficient clinical grade pigment epithelium induction method, a kit, and an application. Provided is a method for rapidly and efficiently inducing retinal pigment epithelium (RPE). IPSCs are directionally induced in three stages, such that an RPE generation duration can be greatly shortened. Specifically, the method comprises using a culture medium containing a small molecule compound for cell culture, the small molecule compound comprising a BMP signaling pathway inhibitor, a Wnt pathway inhibitor, inhibitors for TGF-BI receptors ALK5, ALK4 and ALK7, a ROCK pathway inhibitor, a WNT signaling pathway activator, a VEGFR kinase inhibitor, a GSK signaling pathway inhibitor, a VEGFR kinase inhibitor, vitamins, and the like.

Abstract: The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provides a fusion protein. The fusion protein comprises an extracellular part, an extracellular hinge region, a transmembrane region, and an intracellular region. Most preferably, the amino acid sequence of the fusion protein of the present invention is formed by sequentially connecting SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9 and SEQ ID NO.: 11, and the immune cells expressing the fusion protein have strong killing activity.

Abstract: Disclosed is an efficient and non-genetically modified iPSC-induced, industrialized single clone selection platform, and a use. The platform can efficiently perform reprogramming, and only requires the use of a minimal number of reprogramming factors (OCT4, SOX2, E6, E7). During the single clone separation stage of the present invention, SSEA4/TRA-1-60 is used as a screening marker, and a large number of single cell clones are obtained by means of flow cytometry. The platform described in the present invention has advantages such as high reprogramming efficiency, high safety, easy operation, and large-scale production.

Abstract: Provided are a method for differentiating human induced pluripotent stem cells into oligodendrocytes, and a kit and the use. The method comprises culturing stem cells by means of using at least one of the following culture media: a neural induction complete culture medium, an N2 culture medium, a B27 culture medium and an OPC maturation culture medium. More preferably, the induction of oligodendrocytes by an OPC maturation culture medium with puerarin increases the number of oligodendrocytes by 30% compared with a culture medium without puerarin.

Abstract: Provided in the present disclosure are a KHL polypeptide, and the use thereof in the preparation of a TABP-EIC cell. In addition, also provided in the present disclosure are a KHL polypeptide conjugate, a tumor-antigen-binding polypeptide containing the KHL polypeptide, a DNA molecule, a carrier, a host cell and a pharmaceutical composition. The tumor-antigen-binding polypeptide is composed of the KHL polypeptide, a transmembrane domain and/or a signal transduction domain.